Evidence map›Paper›PMID 33622870›Full record

ArticleIn vivo (Athens, Greece)

Combination Cancer Therapy of a Del1 Fragment and Cisplatin Enhanced Therapeutic Efficiency

Hisataka Kitano, Yoh Masaoka, Atsushi Mamiya, Yusuke Fujiwara, Toshio Miki, Chiaki Hidai

Abstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The Employment of GeneraNutrients · 2022
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hisataka KitanoDivision of Oral Surgery, Nihon University School of Medicine, Tokyo, Japan.
Yoh MasaokaDivision of Oral Surgery, Nihon University School of Medicine, Tokyo, Japan.
Atsushi MamiyaDivision of Oral Surgery, Nihon University School of Medicine, Tokyo, Japan.
Yusuke FujiwaraDivision of Oral Surgery, Nihon University School of Medicine, Tokyo, Japan.
Toshio MikiDivision of Physiology, Nihon University School of Medicine, Tokyo, Japan.
Chiaki HidaiMedical Education Center, Nihon University School of Medicine, Tokyo, Japan hidai.chiaki@nihon-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimCombination cancer therapy is currently under investigation. This study examined the effect of cancer combination therapy using the E3 and C1 (E3C1) domains of developmental endothelial locus-1 (Del1) and cisplatin (CDDP) in murine transplanted tumors. MATERIALS AND

methodsMice with transplanted tumors (A431, SCCKN or SCC-4 cells) were injected intraperitoneally with CDDP and injected locally with nonviral plasmid vectors encoding E3C1. Histochemical analysis of the transplanted tumors was then performed to assess the effects on prognosis.

resultsThe CDDP+E3C1 injected group had reduced tumor growth and longer survival compared to the CDDP injected group. In addition, cell death was observed in the tumor of the CDDP+E3C1 group.. Furthermore, angiogenesis and increased blood vessels were observed together with stromal development.

conclusionThe CDDP+E3C1 treatment resulted in improved survival and poor tumor stromal development in mice with transplanted tumors.

Indexed as

Antineoplastic AgentsNeoplasmsAnimalsCisplatinCombined Modality TherapyGenetic VectorsMiceNeovascularization, PathologicAntineoplastic AgentsCisplatincisplatinCombination cancer therapydevelopmental endothelial locus 1squamous cell carcinomatumor stroma

Identifiers

PMID33622870
PMCPMC8045091

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.